Table 2.

Tumor response by treatment _^† in propensity score-matched cohort.

Variables, n (%) or median (range)	Lenvatinib group N=70	Sorafenib group N=140
Treatment response evaluation, n (%)	53 (75.7)	111 (79.2)
Complete response	1 (1.9)	1 (0.9)
Partial response	4 (7.5)	8 (7.2)
Stable disease	28 (52.8)	49 (40.5)
Progression disease	20 (37.7)	57 (51.4)
Objective response rate‡	9.4%	8.1%
Disease control rate‡	62.3%	48.6%
Durability, month	7 (1.2–15)	9.6 (1.0–24)
Death	28 (40)	91 (65)

^†Treatment response based on those who received image evaluation including Computer tomography or Magnetic resonance image.

^‡The comparison of objective response rate and disease control rate between two groups was 0.776 and 0.029, respectively.